Retraction Note to: Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study

Darinskas, Adas; Paskevicius, Mindaugas; Apanavicius, Gintaras; Vilkevičius, Gintaris; Labanauskas, Liutauras; Ichim, Thomas E.; Rimdeika, Rytis

doi:10.1186/s12967-020-02266-3

Cited by 2 publications

(3 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Darinskas et al included 15 patients with rest pain and some with ulcerations; SVF was injected once or twice in the ischemic limb along the arteries (150). Clinical improvement in terms of pain, meters of claudication and ABI occurred in 86.7% of patients, but only 6 patients out of 15 had ulcers and two patients underwent major amputation, although the amputation sites healed completely.…”

Section: Clinical Trials In No-option Patientsmentioning

confidence: 99%

“…Clinical improvement in terms of pain, meters of claudication and ABI occurred in 86.7% of patients, but only 6 patients out of 15 had ulcers and two patients underwent major amputation, although the amputation sites healed completely. Moreover, the vascular collateral network formation of arteries was observed by digital subtraction angiography upon SVF cell therapy (150).…”

Section: Clinical Trials In No-option Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

Magenta

Florio

Ruggeri³

et al. 2021

Int J Mol Med

View full text Add to dashboard Cite

Cell therapy is becoming an attractive alternative for the treatment of patients with no-option critical limb ischemia (CLI). The main benefits of cell therapy are the induction of therapeutic angiogenesis and neovascularization that lead to an increase in blood flow in the ischemic limb and tissue regeneration in non-healing cutaneous trophic lesions. In the present review, the current state of the art of strategies in the cell therapy field are summarized, focusing on intra-operative autologous cell concentrates in diabetic patients with CLI, examining different sources of cell concentrates and their mechanisms of action. The present study underlined the detrimental effects of the diabetic condition on different sources of autologous cells used in cell therapy, and also in delaying wound healing capacity. Moreover, relevant clinical trials and critical issues arising from cell therapy trials are discussed. Finally, the new concept of cell therapy as an adjuvant therapy to increase wound healing in revascularized diabetic patients is introduced. Contents 1. Introduction 2. Cell therapy: Unfractioned mixed cell population concentrate or pure stem/progenitor cell concentrate 3. Diabetes impairs the angiogenic and regenerative capacity of autologous cell therapy 4. Clinical trials in no-option patients 5. Conclusions and future perspectives

show abstract

Section: Clinical Trials In No-option Patientsmentioning

confidence: 99%

Section: Clinical Trials In No-option Patientsmentioning

confidence: 99%

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

Magenta

Florio

Ruggeri³

et al. 2021

Int J Mol Med

View full text Add to dashboard Cite

show abstract

“…Adipose tissuederived stromal vascular fraction (SVF) contains a variety of cells, including mesenchymal stem cells (MSCs), which is a promising therapeutic option for OA. With the application of conventional liposuction and isolation methods, SVF in adipose and connective tissues can be easily obtained from patients [10]. Michalek et al showed significant improvement in OA symptoms, particularly pain reduction and decrease in nonsteroidal anti-inflammatory drug usage in a large group of 1,128 patients with OA [11].…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis

et al. 2020

View full text Add to dashboard Cite

Background: Osteoarthritis (OA) is progressive degenerative damage to articular cartilage. Current therapeutic options are reduced to control the OA-associated symptoms, leaving the degenerative changes to progress until a joint replacement becomes mandatory. Therefore, therapeutic alternatives are warranted to improve the patient's quality of life. Cell-based therapy is a developing therapeutic modality, showing promising results in the regeneration of injured cartilage and reduction of on-going inflammation within the affected joint. The current retrospective chart review study was aimed to analyze changes in pain and mobility of subjects with OA after stromal vascular fraction (SVF) cell therapy.Methods: Three hundred fifty subjects with hip and knee OA, treated with autologous SVF cells at the Malacky Hospital (Bratislava, Slovakia) in the period from 2015 to 2018, were included in the retrospective chart review study.Results: Seven days after SVF cell therapy, 45.2% of subjects experienced improved pain levels and mobility. Three, 6, and 12 months after therapy, improvement in pain levels reached 75.3%, 84.4%, and 84.9%, and improvement in mobility reached 75.2%, 84.4%, and 84.9%. Conclusions:Our study of 350 subjects with hip and knee OA showed a significant improvement in pain levels and mobility 3, 6, and 12 months compared to 7 days after autologous SVF cell administration. The treatment demonstrated a strong safety profile with no severe adverse events or complications reported. The results of the study are showing that SVF cell therapy was more effective in subjects with arthritis stage III compared to arthritis stages I, II, and IV.

show abstract

Retraction Note to: Stromal vascular fraction cells for the treatment of critical limb ischemia: a pilot study

Cited by 2 publications

References 1 publication

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

Autologous cell therapy in diabetes‑associated critical limb ischemia: From basic studies to clinical outcomes (Review)

A Retrospective Study of Stromal Vascular Fraction Cell Therapy for Osteoarthritis

Contact Info

Product

Resources

About